Hypogonadism and its treatment among prostate cancer survivors.
Edward J ChoiPerry XuFarouk M El-KhatibLinda M HuynhFaysal A YafiPublished in: International journal of impotence research (2020)
Adult-onset hypogonadism (AOH) is associated with sexual dysfunction, poor bone mineralization, decreased muscle mass, metabolic syndrome disorder, and cognitive suppression. Historically, testosterone has been contraindicated in men with a history of prostate cancer. However, there has been a modern resurgence in re-evaluating this belief. Not only can testosterone be safely utilized to alleviate AOH symptoms in prostate cancer survivors, it has been also touted as a treatment option for aggressive prostatic cancer. While much work remains in understanding the relationship between testosterone and prostate cancer, those who survive this disease should not be automatically turned away from an opportunity to be treated and restored.
Keyphrases
- prostate cancer
- replacement therapy
- radical prostatectomy
- metabolic syndrome
- young adults
- benign prostatic hyperplasia
- oxidative stress
- smoking cessation
- squamous cell carcinoma
- childhood cancer
- postmenopausal women
- bone mineral density
- adipose tissue
- cardiovascular disease
- skeletal muscle
- depressive symptoms
- insulin resistance
- sleep quality
- soft tissue